Skip to content

Typhlitis study.

Identification of predictive parameters for typhlitis in AML patients treated with intensive chemotherapy.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21843
Enrollment
45
Registered
2009-05-06
Start date
2008-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia Acute myeloide leukemie

Interventions

1. Blood and stool samples will be collected
2. CT-scan of abdomen at day 10-12
3. Mucositis score will be determined
4. DNA isolation from normal peripheral blood.

Sponsors

Prof.dr. E. Vellenga Dept. of Hematology University Medical Center Groningen P.O. Box 30.001 9700 RB Groningen The Netherlands Phone: +31 50 361 61 61 E-mail: e.vellenga2int.umcg.nl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years; 2. Diagnosed with AML and treated with intensive chemotherapy.

Exclusion criteria

Exclusion criteria: Ineligible to perform the tests.

Design outcomes

Primary

MeasureTime frame
1. Defining the severity of epithelial dysfunction measured with mucositis score, the stool volume, the calprotectin level in the stool, the urinary Cr EDTA excretion and serum IL-8 and CRP levels; 2. Typhlitis based on clinical symptomatology and CT-scanning abdomen.

Secondary

MeasureTime frame
Before and after treatment with chemo different parameters will be examined.

Contacts

Public ContactE. Vellenga

University Medical Center Groningen (UMCG), Department of Hematology, P.O. Box 30001

e.vellenga@int.umcg.nl+31 (0)50 3612354

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)